Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Teva Announces U.S. Supreme Court Will Hear Its Appeal on COPAXONE(R) Patent
Comparing the biological impact of glatiramer acetate with the biological impact of a generic.
Health Canada Approves PLEGRIDY™ (peginterferon beta-1a) for Adults with Relapsing Remitting Multiple Sclerosis
T cells become licensed in the lung to enter the central nervous system.
Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.
Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
Stress Management and Multiple Sclerosis: A Randomized Controlled Trial.
Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats.
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Identification of the LDL Receptor-Related Protein-1 Interactome in Central Nervous System myelin suggests a role in the clearance of necrotic cell debris.
Rare variants in the CYP27B1 gene are associated with multiple sclerosis.
Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions.
Predicted structure of MIF/CD74 and RTL1000/CD74 complexes.
Vitamin D-dependent rickets, HLA-DRB1, and the risk of multiple sclerosis.
Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study.
Demyelination affects temporal aspects of perception: An optic neuritis study.
Lipocalin 2 is present in the EAE brain and is modulated by natalizumab.
High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases.
Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
The value of specialty pharmaceuticals - a systematic review.
Control of experimental autoimmune uveoretinitis by low dose T cell vaccination.
Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.
Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis.

Pages